N@N

Optimer Pharmaceuticals Inc (NASDAQ:OPTR), Down By 13.78% ($2.06) From $14.962 After BUYINS.NET Report Predicted Stock Would Go

^{Published on 2012-08-03 07:49:27 - WOPRAI}
 

August 3, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Friday, July 13th 2012 stating that Optimer Pharmaceuticals Inc (NASDAQ:OPTR) was expected to go Down due to the Bearish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=optr&id=292912

At the time this story was written, Optimer Pharmaceuticals Inc (NASDAQ:OPTR) is Down By $2.06 (13.78%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

Optimer Pharmaceuticals Inc (NASDAQ:OPTR) - Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide. It develops products that treat gastrointestinal infections and related diseases. The companys two late-stage anti-infective product candidates include Fidaxomicin, the lead product candidate and an antibiotic for the treatment of clostridium difficile-infections, which completed two Phase III clinical trial; and Prulifloxacin, a prodrug in the fluoroquinolone class of antibiotics, which completed two Phase III trials for the treatment of infectious diarrhea, including travelers diarrhea. It also develops product candidates using its proprietary technology Optimer One-Pot Synthesis, a drug discovery platform and a computer-aided technology that enables the synthesis of carbohydrate-based compounds. In addition, the companys other pipeline product candidates consist of CEM-101 (OP-1068), a macrolide and ketolide antibiotic for the treatment of upper and lower respiratory tract infections; OPT-88, a disease-modifying intra-articular therapy for osteoarthritis; and OPT-822/OPT-821, a carbohydrate-based immunostimulant therapy for the treatment of metastatic breast cancer. Additionally, it licensed rights to Cempra Pharmaceuticals, Inc. to develop CEM-101; and granted rights to Optimer Biopharmaceuticals, Inc. to develop OPT-88 and OPT-822/821. Further, the company has collaborative agreements with Par Pharmaceuticals, Inc.; Nippon Shinyaku, Co., Ltd.; Memorial Sloan-Kettering Cancer Center; and Scripps Research Institute. Optimer Pharmaceuticals was founded in 1998 and is based in San Diego, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net